Details for New Drug Application (NDA): 065130
✉ Email this page to a colleague
NDA 065130 describes SUPRAX, which is a drug marketed by Lupin Ltd, Lederle, and Lupin Pharms, and is included in eight NDAs. It is available from two suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the SUPRAX profile page.
The generic ingredient in SUPRAX is cefixime. There are fourteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the cefixime profile page.
The generic ingredient in SUPRAX is cefixime. There are fourteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the cefixime profile page.
Summary for 065130
| Tradename: | SUPRAX |
| Applicant: | Lupin Pharms |
| Ingredient: | cefixime |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 400MG | ||||
| Approval Date: | Feb 12, 2004 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
